Moreover, a recent protein–protein interaction study identified the direct interaction between PAR2 and SARS-CoV-2 viral protein, ORF9c [15], which suggests that PAR2 is one of the druggable potential targets to treat severe COVID-19-associated hyperinflammation. Here, F2RL1 is linked to COVID-19.